Market Signal Briefing

Mining difficulty on the Bitcoin blockchain has dropped by the most since China’s 2021 ban on crypto mining.

Mining difficulty is an average measure of how many hash operations miners must perform to mine a block. According to data from the Bitcoin network explorer Mempool, the difficulty decreased by approximately 11.2%. That’s the most since the China mining ban five years ago, when the hashrate, the total computational power used to mine blocks, dived 50% to 58 exahashes per second (EH/s) and BTC was gyrating around $30,000.

China declared a sweeping ban on crypto mining and started implementing a crackdown on cryptocurrencies in May 2021, leading to multiple negative difficulty adjustments between May and July 2021, ranging between 12.6% and 27.9%, historic data from CoinWarz shows.

Bitcoin’s mining difficulty stands at 125.86 trillion — down from 141.67T and took effect at block 935,429. This was also the 10th-largest negative percentage adjustment of all time.

The difficulty is recalibrated every 2,016 blocks to ensure that blocks continue to be mined at roughly 10-minute intervals. Prior to the latest difficulty adjustment, average block times hovered at approximately 11.4 minutes, slightly above the network’s 10-minute target.

Advertisement  

The sharp downward adjustment came amid a broad crypto market rout. The price of Bitcoin recently fell by over 50% from its all-time peak of around $126,000 to $60,000 lows, spurred by massive spot BTC exchange-traded fund (ETF) outflows and a wider risk-off sentiment across stocks and commodities.

The drop in mining difficulty provides some relief for miners by slightly improving the chances that each unit of computing power will secure a block reward. However, whether that provides meaningful financial relief will largely depend on Bitcoin’s price trajectory in the coming period.

At the time of writing, Bitcoin was trading at $69,661, up 0.88% over the past 24 hours. It’s now roughly 9.9% lower than it was a week ago, according to crypto price aggregator TradingView.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

China has ordered major banks to reduce their U.S. Treasury holdings, signaling a major shift in global finance. The move reflects rising concerns over U.S. debt risks and market volatility

Experts belive that this decision could create new opportunities for Bitcoin and the overall crypto market. 

China Orders Banks to Reduce U.S. Bond ExposureReports suggest that Chinese regulators have warned banks about “concentration risks” and rising volatility in U.S. Treasuries. Financial institutions have been advised to reduce oversized positions and limit further purchases.

China’s holdings of U.S. Treasuries have already been falling for years. Official data shows that the country now holds around $682.6 billion in Treasuries, the lowest level in 17 years and far below its peak of $1.3 trillion a decade ago.

Over the past 14 years, China has reduced more than $500 billion in U.S. debt while steadily increasing its gold reserves. 

In fact, Beijing has been buying gold for 18 months in a row, showing a clear preference for hard assets over government bonds.

China’s Long-Term Move Away From U.S. DebtImportantly, this order does not affect China’s official foreign exchange reserves held by the central bank. Instead, it targets commercial banks and their growing exposure to dollar-denominated assets. 

With China stepping back as one of the biggest buyers of U.S. Treasuries, the traditional support system for American bonds is weakening. 

The absence of such a large buyer could lead to higher volatility in the bond market and rising interest rates.

What This Means for Bitcoin and Cryptonvestors look for safer options. In the past, gold has benefited the most from this trend. Gold prices jumped nearly 72% in a year and recently touched a record high of around $5,600. Now prices are easing as some investors book profits.

Usually, after gold peaks, investors shift part of their money into Bitcoin. This is because Bitcoin is seen as a digital store of value, similar to gold.

Right now, Bitcoin has dropped from its all-time high of $126,000 and is trading near $69,712. Many investors see this as a discounted buying level.

Other major cryptocurrencies like, ETH, SOL, XRP, ADA & Doge also down 40% to 70% from their highs. This market pullback is making crypto assets more attractive for long-term buyers.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Active Currencies 18947

Market Cap $2,441,730,032,249.20

Bitcoin Share 57.11%

24h Market Cap Change $-1.58

AMBCrypto

Ethereum supply falls to 2016 levels – Is ETH’s market unstable?

Journalist

Posted: February 9, 2026

Samyukhtha L KM is a Financial Journalist and Market Analyst at AMBCrypto whose work is defined by one central question: Is the latest trend in blockchain hype, or history in the making? Her expertise is built on a strong academic foundation, with a Master’s in Journalism and Mass Communication from Amity University and a Bachelor’s in Commerce from the University of Madras. This dual qualification equips her with a unique skill set: the financial acumen to dissect market mechanics and the journalistic rigor to investigate and communicate complex subjects with clarity. Samyukhtha specializes in analyzing the socio-economic impact of blockchain adoption and assessing the viability of new market narratives. This includes a focus on high-velocity, community-driven assets such as memecoins, where she evaluates sentiment and fundamentals. She is dedicated to providing readers with insightful, well-researched commentary that looks beyond immediate market moves to understand the long-term implications of decentralized technology.

NatWest Group logo is seen in this illustration taken January 7, 2026. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesNatWest aims to expand wealth management business with Evelyn acquisitionDeal "transformational" for NatWest, analyst saysDeal funded from existing resourcesNatWest announces 750 million pound share buybackFeb 9 (Reuters) - NatWest Group (NWG.L), opens new tab has agreed to buy one of Britain's largest wealth managers, Evelyn Partners, for 2.7 billion pounds ($3.68 billion), including debt, in a bid to expand its wealth management business, the British lender said on Monday.

NatWest is following rivals such as HSBC and Lloyds in boosting wealth management offerings in recent years, as British lenders increasingly target the fee-based business to offset an expected decline in interest income as central bank rates fall.

The Week in Breakingviews newsletter offers insights and ideas from Reuters' global financial commentary team. Sign up here.

The combined company will have total assets under management and administration of 127 billion pounds.

NatWest expects the deal to generate about 100 million pounds in annual cost savings and also announced a 750 million pound share buyback.

The deal creates Britain's largest private banking and wealth management business and transforms NatWest Group's savings and investment offering for its 20 million customers, the British lender said.

TRANSFORMATIONAL DEAL FOR NATWESTEvelyn's private equity shareholders, Permira and Warburg Pincus, kicked off a sale of the wealth manager last year, which also drew interest from Barclays (BARC.L), opens new tab, Lloyds (LLOY.L), opens new tab, and the Royal Bank of Canada (RY.TO), opens new tab, Reuters reported.

"We are somewhat surprised that NWG appear to have come out on top, given how tightly the CEO holds the bank's purse strings," RBC Capital Markets analyst Benjamin Toms said in a note.

"Although we consider this to be a bolt on transaction, it would be transformational, filling the gap NWG has in its affluent wealth offering."

Permira has Evelyn Partners, formerly known as Tilney Smith & Williamson, since 2014, funding its growth into a wealth manager overseeing 63 billion pounds in client assets.

The transaction will be funded from existing resources and is expected to reduce NatWest's core equity tier 1 ratio by about 130 basis points, the bank said.

($1 = 0.7344 pounds)

Reporting by Prerna Bedi and Raechel Thankam Job in Bengaluru and Lawrence White in London; Editing by Rashmi Aich, Kirsten Donovan

Our Standards: The Thomson Reuters Trust Principles., opens new tab

The sale to CVC Capital Partners marks the final step in its plan to fully focus on human nutrition, health and beauty.

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of America's Car-Mart, Inc. (NASDAQ: CRMT) resulting from allegations that America's Car-Mart may have issued materially misleading business information to the investing public.

So What: If you purchased America's Car-Mart securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=46025 https://rosenlegal.com/submit-form/?case_id=39889or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On September 4, 2025, during market hours, Benzinga published an article entitled "America's Car-Mart Stock Plunges After Sales Volume Dip, Delinquency Uptick." The article stated that America's Car-Mart, Inc. stock was trading "lower after the company reported first-quarter results. The company reported a first-quarter loss of 69 cents per share, compared with a net loss of 15 cents per share in the year-ago period."

On this news, America's Car-Mart's stock fell 18.2% on September 4, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

LEADING EDGE MATERIALS AND ASCENSION EARTH RESOURCES TEAM UP ON HEAVY RARE EARTHS RECOVERY FROM NORRA KÄRR EUDIALYTE

Strategic collaboration aims to assess innovative recovery methods for Heavy Rare Earth Elements (“HREE”) from Norra Kärr Eudialyte mineralisation.Leading Edge Materials 100% owned subsidiary Greenna Mineral AB and Ascension Earth Resources have entered into a Memorandum of Understanding.Both parties will negotiate in good faith toward a definitive collaboration agreement for a larger-scale pilot project, contingent on successful evaluation project outcomes. Vancouver, February 8, 2026 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) (FRA: 7FL) is pleased to announce that its 100% owned Swedish subsidiary Greenna Mineral AB (“GMAB”) has signed an MoU with Ascension Earth Resources (“Ascension”).

Evaluation Project

Under the MoU, GMAB will supply eudialyte samples from the Norra Kärr deposit to Ascension, which will conduct comprehensive laboratory analysis and processing testwork using its proprietary technology.

The collaboration aims to assess the technical and commercial feasibility of rare earth extraction and recovery from the HREE bearing eudialyte mineralisation at Norra Kärr.

The Evaluation Project will focus on:

Conducting detailed analysis of eudialyte samples to determine composition, purity, and recovery potential.Testing leach behaviour and assessing suitability for commercial-scale processingDeveloping preliminary processing concepts tailored to the Norra Kärr mineralisationEvaluating the commercial viability of rare earth extraction. Path to Commercial Collaboration

Subject to successful outcomes from the evaluation phase, both parties have committed to negotiate in good faith toward a definitive collaboration agreement. This subsequent agreement would govern a larger-scale pilot project.

Kurt Budge CEO comments:         

"This partnership represents an important step forward in advancing the Norra Kärr HREE Project.

By combining our world-class resource with Ascension's innovative processing technology, we aim to unlock new possibilities for sustainable heavy rare earth production in Europe.

We already have a PFS flowsheet from 2015 to produce mixed rare earth oxide but we are enthusiastic about trying new innovative methods, such as the ones being developed by Ascension, to maximise the recovery of heavy rare earth elements from Norra Kärr.”

Motoaki Sumi CEO of Ascension Earth Resources comments:

"We are excited to collaborate with Leading Edge Materials on an evaluation programme focused on heavy rare earth elements recovery from the Norra Kärr eudialyte mineralisation.

Norra Kärr is a strategically significant European rare earth resource with important implications for the development of a resilient European supply chain for critical minerals.

Through this collaboration, we aim to advance efficient and environmentally responsible approaches to critical mineral recovery, aligned with Ascension’s core mission.

Ascension is a University of Oxford spin-out company developing technologies to recover critical minerals from novel resources.”

___________________________________________________________________________________.

On behalf of the Board of Directors,
Leading Edge Materials Corp.

Kurt Budge, CEO

For further information, please contact the Company at:
[email protected]
www.leadingedgematerials.com

About Leading Edge Materials

Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defence applications. The Company’s portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden), and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania).

About Ascension Earth Resources Limited

Ascension Earth Resources Limited is a UK-based company developing proprietary technology for rare earth element analysis and recovery, harnessing geothermal energy to create a secure and sustainable onshore critical mineral supply chain.
https://ascension.global/
https://www.linkedin.com/company/ascension-earth-resources/
Additional Information

The information was submitted for publication through the agency of the contact person set out above, on February 8, 2026, at 23:30 AM Vancouver time.

Leading Edge Materials is listed on the TSXV under the symbol “LEM”, OTCQB under the symbol “LEMIF” and Nasdaq First North Stockholm under the symbol “LEMSE”. Svensk Kapitalmarknadsgranskning (“SKMG”) is the Company’s Certified Adviser for the Nasdaq First North Growth Market (Stockholm) and may be contacted via email [email protected] or by phone +46 (0)8 913 008.

Reader Advisory

This news release may contain statements which constitute “forward-looking information”, including statements regarding the plans, intentions, beliefs and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may”, “would”, “could”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions, as they relate to the Company, or its management, are intended to identify such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those in the forward-looking statements as a result of various factors, including, but not limited to, fluctuations in market prices, changes in the Company’s intended use of proceeds from the Private Placement, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.

20260208 PR LEM Ascension FINAL

The acquisition more than doubles NatWest's assets under management and administration to £127 billion.

Qwen and Alibaba logos are seen in this illustration taken, January 29, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

BEIJING, Feb 9 (Reuters) - Alibaba's (9988.HK), opens new tab artificial intelligence chatbot Qwen has temporarily stopped issuing coupons due to customer overload, hampering a new campaign to promote the tool's capabilities beyond simply answering questions to assist shopping.

Qwen began offering coupons to users on Friday that allow for in-app purchases from Alibaba-owned retail platforms using chatbot prompts alone. The initiative is the first phase in a 3-billion-yuan ($433 million) plan to attract more users to the chatbot during China's annual Spring Festival holiday.

Learn about the latest breakthroughs in AI and tech with the Reuters Artificial Intelligencer newsletter. Sign up here.

Since last month, Alibaba has sought to make Qwen a one-stop shop where users can access its other apps directly in the chatbot and complete payments, much like Google (GOOGL.O), opens new tab integrates its Gemini chatbot into apps like Maps.

But the rollout of what the e-commerce giant calls the chatbot's Agentic AI strategy has been marred by technical difficulties since the start of the coupon giveaway.

Alibaba said that 10 million orders were placed within the first nine hours of the campaign. And faced with an overwhelming flood of attempted orders over the weekend, Qwen announced on Sunday on its official Weibo channel that it was overloaded and pleaded for users to give the chatbot a break.

Repeated purchase prompts on Monday generated different versions of a refusal, citing user oversubscription, Reuters checks showed.

"Everyone's enthusiasm for experiencing AI shopping is too high! Currently there are too many participants in 'Qwen free order', we are working tirelessly to maintain the campaign's experience," replied Qwen to one of the purchase prompts on Monday.

The chatbot added that shoppers would still have time to redeem their coupons, which will remain valid until February 28.

Alibaba declined to comment further on the technical difficulties.

($1 = 6.9289 Chinese yuan renminbi)

Reporting by Eduardo Baptista; Editing by Miyoung Kim and Joe Bavier

Our Standards: The Thomson Reuters Trust Principles., opens new tab

HomeStock IdeasLong IdeasBasic Materials

SummaryAmcor remains a strong buy, supported by robust fundamentals, attractive yield, and ongoing post-merger synergies, despite recent price appreciation.AMCR delivered 14% EPS growth in H1’FY26, reaffirmed FY26 guidance, and still expects $650M in merger synergies over three years, with $93M realized in H1.Dividend yield stands at 5.4%, with a sustainable <65% payout ratio, enabling continued buybacks and reinvestment alongside portfolio optimization initiatives.Valuation models imply intrinsic value well above current levels, while consumer weakness and refinancing risks are offset by AMCR’s quality and cash flow resilience. Richard Drury/DigitalVision via Getty Images

Introduction The last time I highlighted Amcor (AMCR), I called them a “Reliable High-Yield Dividend Aristocrat You Can Still Buy Cheap,” highlighting their clear undervaluation, strong synergies expected following the Berry Global merger, and the strong ~6.4% dividend at the time with a great

Analyst’s Disclosure: I/we have a beneficial long position in the shares of AMCR either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents".

The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the treatment of neurological diseases and disorders. Of particular interest is Parkinson's disease, which is a neurodegenerative condition afflicting over 10 to 12 million globally, and it is cited as the 2nd most common neurodegenerative disorder after dementia. Progressive symptoms of Parkinson's disease include unilateral movement issues, typically presenting as a slight tremor and quiet speech in the early stages, through to severe disability that impacts eating, bathing and dressing, complemented by cognitive decline.

Depletion of the neurotransmitter dopamine in the brain is the key driver of Parkinson's. Direct supplementation with dopamine is not currently a viable option, due to it being unable to cross the blood-brain barrier, and treatments most typically involve oral administration of the dopamine precursor, levodopa (L-dopa). As Parkinson's is a progressive disease also impacting the health of dopaminergic neurons, their gradual decline in numbers is inevitable, reaching a threshold that renders supplementation with L-dopa ineffective.

PreveCeutical has now developed an approach for the delivery of central nervous system (CNS)-active drugs, such as dopamine, directly to the brain, and formulations that are adapted for this delivery mode. By supplying the native neurotransmitter (dopamine) directly to the brain, the Company proposes circumventing the need to administer L-dopa, dopamine agonists and other therapeutics progressively prescribed for the management of Parkinson's across the spectrum of disease. Furthermore, this approach has the potential to offer patients in the advanced stages of Parkinson's a safe and effective treatment option, through direct replenishment of dopamine in the brain, potentially circumventing the need for advanced/invasive treatments.

More broadly, PreveCeutical's novel approach has the potential to address historical bottlenecks in the delivery of a range of peripherally-restricted therapeutics for CNS conditions, and it is actively exploring options to exploit these opportunities.

Commenting on the filing, PreveCeutical Chief Executive Officer Stephen Van Deventer stated, "Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain. Our technology aims to change that, and we believe it represents an important step toward transforming the treatment landscape for Parkinson's disease and other central nervous system disorders."

The Company is not making any express or implied claims that its product and approach has the ability to manage Parkinson's disease at this time.

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

Certain information in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include: that the Company's patent will be successfully granted by the regulators; that the Company's technology for delivering drugs directly to the brain by directly crossing the blood-brain barrier will be successful and that the Company's technology will be a treatment for Parkinson's disease or have any positive effects on those with Parkison's disease. Forward-looking information is based on reasonable assumptions that have been made by PreveCeutical as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of PreveCeutical to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the risk of PreveCeutical not obtaining the patent applied for; the risk that the technology which is the subject of the patent not successfully working for the administration of drugs directly through the blood-brain barrier; the risk that the Company will not have access to the necessary capital to operate its business; the accuracy of PreveCeutical's projections and estimates; interest and exchange rates; competition; share price fluctuations; actual results of activities; government regulation; political or economic developments; environmental risks; insurance risks; capital expenditures; operating or technical difficulties in connection with research and development activities; personnel relations; changes and volatility in project parameters as plans continue to be refined; the inherent uncertainties regarding cost estimates, financing, cost overruns, availability of materials and equipment, timeliness of government approvals, taxation, political risk and related economic risk; global financial conditions; the market price of PreveCeutical's securities; ability to access capital; changes in interest rates; liabilities and risks inherent in research and development operations; the potential influence of or reliance upon PreveCeutical's business partners, and the adequacy of insurance coverage. Forward-looking information is based on certain assumptions that PreveCeutical believes is reasonable, including that the technology which is the subject of the patent is successful in the administration of drugs directly through the blood-brain barrier; sufficient working capital will be available for operation of the business; that the general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed on reasonable terms and that PreveCeutical will not experience any material labour dispute, accident, or failure of plant or equipment, as well as the risks and uncertainties which are more fully described in the Company's annual and quarterly management's discussion and analysis and in other filings made by the Company with Canadian securities regulatory authorities under the Company's SEDAR+ profile. Although PreveCeutical has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. PreveCeutical does not undertake to update any forward-looking information contained herein or that is incorporated by reference herein, except in accordance with applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283161

Source: PreveCeutical Medical Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Milano, 9 febbraio 2026 – 21shares, società leader a livello globale nello sviluppo e nel lancio di ETP su criptovalute, con sedi a Zurigo, Londra e New York, annuncia oggi la quotazione di 27 ETP - parte della sua gamma globale - sul mercato ETF Plus di Borsa Italiana, Gruppo Euronext. 

Per la prima volta in Italia gli investitori professionali avranno la possibilità di accedere a strumenti finanziari che permettono investimenti in criptovalute tramite ETP quotati su Borsa Italiana.

Si tratta del più grande lancio di ETP cripto su ETFplus e posiziona 21shares come il leader di settore anche in Italia per quanto riguarda la proposta di opzioni liquide, trasparenti, e dalla struttura nota per investire nelle principali criptovalute sul mercato tramite strategie collateralizzate.

Con questa quotazione l’Italia si allinea a tutti i principali mercati europei: ora gli investitori professionali italiani potranno crearsi una posizione verso numerosi asset digitali, tra cui Bitcoin, Ethereum, Ripple e Solana. Per quanto riguarda quest’ultimo, la società possiede la più grande riserva europea, con un valore di 1,4 miliardi di dollari.

Il vantaggio di investire attraverso uno strumento quotato come l’ETP permette agli investitori di esporsi all’andamento del prezzo di uno o più asset digitali, senza doverli detenere direttamente nel proprio portafoglio di investimenti, come accade per l’acquisto diretto tramite le piattaforme di exchange online. Gli ETP sulle cripto sono scambiati allo stesso modo degli ETF e offrono agli investitori la liquidità e la trasparenza che si aspettano da un prodotto quotato.

Duncan Moir, Presidente di 21shares, ha dichiarato: “Siamo elettrizzati per il debutto di 21shares in Italia., il Paese è sempre stato un punto di riferimento per il nostro business in Europa. Questa quotazione sottolinea il crescente riconoscimento internazionale delle cripto come asset class di investimento, nonché il nostro impegno nel rendere l'accesso alle criptovalute più semplice ed immediato per gli investitori di tutto il mondo.”

Massimo Siano, Vicepresidente e Responsabile per il Sud Europa di 21shares, ha affermato: “L’Europa è stata il pioniere mondiale negli investimenti in criptovalute tramite ETP, che sono stati quotati nelle borse del Vecchio Continente ben prima che gli ETF sulle cripto fossero quotati negli Stati Uniti. Siamo quindi molto felici di poter proporre le nostre soluzioni anche agli investitori italiani. Crediamo che le criptovalute siano un asset class fondamentale per diversificare al meglio il portafoglio. Con il lancio su Borsa Italiana, mettiamo a disposizione la più vasta gamma di ETP su asset digitali, per cercare di rispondere al meglio alle loro richieste e necessità.”

Con 59 ETP quotati in Europa e circa 6 miliardi di dollari di asset in gestione a livello globale, 21shares continua a essere leader di settore nel fornire un’esposizione accessibile e trasparente al crescente ecosistema degli asset digitali.

Nome Ticker ISIN Fee annua 21shares Solana Core Staking ETPCSOLCH13850843840.35%21shares XRP ETPAXRPCH04546640432.50%21shares Bitcoin Core ETPCBTCCH11990676740.10%21shares Ethereum Core Staking ETPETHCCH12097631300.10%21shares Sui Staking ETPASUICH13606121592.50%21shares Crypto Basket Index ETPHODLCH04456892080.99%21shares Cardano ETPAADACH11027287502.50%21shares Chainlink ETPLINKCH11000834712.50%21shares Binance BNB ETPABNBCH04964541552.50%21shares Avalanche Staking ETPAVAXCH11352020882.50%21shares Aave ETPAAVECH11352021202.50%21shares Stellar ETPAXLMCH11095755352.50%21shares Crypto Basket 10 Core ETPHODLXCH11352021790.49%21shares Polkadot ETPADOTCH05933315612.50%21shares Bitcoin Cash ETPABCHCH04755522012.50%21shares Bitcoin Gold ETPBOLDCH11468823080.65%21shares Uniswap ETPAUNICH11352020962.50%21shares Ondo ETPONDOCH13963899212.50%21shares Lido DAO ETPLIDOCH12750433182.50%21shares Polygon ETPPOLYCH11295384482.50%21shares Crypto Mid-Cap Index ETPALTSCH11306756762.50%21shares Hedera ETPHDRACH14566076832.50%21shares Artificial Superintelligence Alliance ETPAFETCH14808213752.50%21shares Bittensor ETPATAOCH14954169712.50%21shares Maple Finance ETPSYRUPCH14954169892.50%21shares Morpho ETPMORPHCH15061670272.50%21shares Canton Network ETPCANTNCH15031279172.50% FINE

21Shares AG

21Shares è uno dei principali emittenti globali di prodotti negoziati in borsa (ETP) su criptovalute e offre la più ampia gamma di ETP cripto disponibile sul mercato. La società è stata fondata con l’obiettivo di rendere le criptovalute più accessibili agli investitori e colmare il divario tra finanza tradizionale e finanza decentralizzata. Nel 2018, 21Shares ha quotato il primo ETP cripto interamente collateralizzato al mondo, sviluppando un track record di sette anni nella creazione di fondi cripto, oggi quotati su alcune delle principali e più liquide borse al mondo. Supportata da un team di ricerca specializzato, tecnologia proprietaria e una profonda esperienza nei mercati finanziari, 21Shares offre soluzioni d’investimento innovative, semplici ed efficienti.

21Shares è una società controllata da FalconX, uno dei principali prime broker di asset digitali a livello globale. 21Shares opera in modo indipendente rispetto a FalconX, pur sfruttandone strategicamente le risorse e la portata globale per accelerare la propria missione e sbloccare nuove opportunità di crescita. Per maggiori informazioni, visitare www.21shares.com.

Andrea Bianchi – [email protected]

Luca Maranesi – [email protected]

DISCLAIMER

This document is not an offer to sell or a solicitation of an offer to buy or subscribe for securities of 21Shares AG in any jurisdiction. Neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever or for any other purpose in any jurisdiction. Nothing in this document should be considered investment advice.

This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful.

This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan. The securities of 21Shares AG to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States.

Within the United Kingdom, this document is only being distributed to and is only directed at: (i) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”); or (iii) persons who fall within Article 43(2) of the Order, including existing members and creditors of the Company or (iv) any other persons to whom this document can be lawfully distributed in circumstances where section 21(1) of the FSMA does not apply. The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Exclusively for potential investors in any EEA Member State that has implemented the Prospectus Regulation (EU) 2017/1129 the Issuer’s Base Prospectus (EU) is made available on the Issuer’s website under www.21Shares.com.

The approval of the Issuer’s Base Prospectus (EU) should not be understood as an endorsement by the SFSA of the securities offered or admitted to trading on a regulated market. Eligible potential investors should read the Issuer’s Base Prospectus (EU) and the relevant Final Terms before making an investment decision in order to understand the potential risks associated with the decision to invest in the securities. You are about to purchase a product that is not simple and may be difficult to understand.

This document constitutes advertisement within the meaning of the Prospectus Regulation (EU) 2017/1129 and the Swiss Financial Services Act (the “FinSA”) and not a prospectus. The 2024 Base Prospectus of 21Shares AG has been deposited pursuant to article 54(2) FinSA with BX Swiss AG in its function as Swiss prospectus review body within the meaning of article 52 FinSA. The 2024 Base Prospectus and the key information document for any products may be obtained at 21Shares AG's website (https://21shares.com/ir/prospectus or https://21shares.com/ir/kids).

###

Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - Inspiration Energy Corp. (CSE: ISP) (WKN: A40GPX) (OTCID: ISPNF) ("Inspiration" or the "Company") was recently granted a drill permit for the Rottenstone North gold/copper project in Northern Saskatchewan and is now in the final stages of drill hole planning and expects to commence drilling shortly. Inspiration is one of the largest landholders in what is rapidly emerging as one of Canada's most exciting new volcanogenic massive sulphide (VMS) and gold exploration districts.

"Inspiration has a 100 percent ownership in over 85,000 acres in the Rottenstone Gold/Copper camp," stated Charles Desjardins, chief executive officer of Inspiration. "We are strategically positioned along trend with recent discoveries and have cutting-edge satellite data identifying multiple gold-copper targets. Our technical team is finalizing drilling plans right now, and we anticipate launching our first drilling program shortly, at a time with historically high commodity prices. Inspiration has a tiny market cap and success in the ground could lead to outsized positive results. Management is very optimistic about the next few months with possible game-changing drilling results upcoming."

Figure 1: Location of Inspiration's Rottenstone North and West properties relative to the property of Ramp Metals, along with the interpreted massive sulphide and gold trends in the district.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11094/283150_8a5d0dc7f4536aff_001full.jpg

The Rottenstone North project (4,512 hectares), along with the acquisition of the Rottenstone West project (31,011 hectares), this past August (see Company news release Aug. 22, 2025), brings the total coverage of this exciting new VMS-gold district and trend to over 35,500 hectares (86,487 acres).

The Rottenstone North and West gold and base metal projects are located immediately west and southwest of Ramp Metals Inc.'s discoveries on its copper-gold sulphide targets at Rush (see Ramp Metals' news release dated April 29, 2015) and Ranger (see Ramp Metals' news release June 17, 2015).

With just over 40 million shares outstanding, Inspiration offers shareholders strong upside leverage to exploration success. Its tight capital structure, combined with large-scale landholdings, advanced geophysics and near-term drill readiness, positions the Company to participate meaningfully in one of Canada's most promising new discovery corridors.

Inspiration's Rottenstone projects are located along the same northeast-southwest-trending geological structures that host multiple high-grade showings in the region, including 73.55 g/t Au over 7.5 metres at the Ranger showing and 1.61% Cu at the Rush VMS discovery (see Ramp Metals' news release June 17, 2024).

Notably, historical work on the Rottenstone West project identified multiple massive sulphide occurrences as early as the 1950s. These areas remain untested by modern exploration methods, presenting compelling targets for new discoveries within a top-tier mining jurisdiction, as ranked by the Fraser Institute.

Recently, at the 100%-owned Rottenstone North gold/copper project, the Company completed an Advanced Atomic Mineral Resonance Tomography (AMRT) satellite survey. The AMRT survey identified numerous high-priority gold and copper targets along the eastern property boundary of Rottenstone North -- parallel and on trend with Ramp's Rush copper-gold-silver discovery, located just a few kilometres away. Inspiration's planned drilling program, scheduled for early 2026, will test several of these targets.

Management cautions that past results or discoveries on properties in proximity to Inspiration may not necessarily be indicative of the presence of mineralization on the Company's properties.

National Instrument 43-101 Disclosure

Dr. Scott Jobin-Bevans, P.Geo. (APEGS No. 82498; PGO No. 0183), an independent adviser to the Company, is a qualified person as defined by NI 43-101, Standards of Disclosure for Mineral Projects. Dr. Jobin-Bevans has reviewed and approved the technical content in this news release.

About Inspiration Energy Corp.

Inspiration Energy is a Canadian mineral exploration company focused on acquiring and developing highly prospective gold and base metal properties. The Company's flagship assets, Rottenstone North and Rottenstone West, position it as one of the largest landholders in one of Canada's newest and most exciting gold-copper VMS (volcanogenic massive sulphide) discovery corridors. For more information, please refer to the Company's information available on SEDAR+ (www.sedarplus.ca).

On Behalf of the Board of Directors
Charles Desjardins
CEO, President and Director
Phone: 604-808-3156
Email: [email protected]

Neither the Canadian Stock Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release.

FORWARD-LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR+ in Canada (available at www.sedarplus.ca).

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283150

Source: Inspiration Energy Corp.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.

So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=15814 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On November 2, 2025, Alvotech issued a press release entitled "Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05." It stated that the "U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for Alvotech's Biologics License Application (BLA) for AVT05, in a prefilled syringe and autoinjector presentations[.]" Further, the "CRL noted that certain deficiencies, which were conveyed following the FDA's pre-license inspection of Alvotech's Reykjavik manufacturing facility that concluded in July 2025, must be satisfactorily resolved before this BLA for AVT05 can be approved."

On this news, Alvotech's stock price fell 34% on November 3, 2025, and nearly 4% on November 4, 2025.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions.  Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - February 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws.

On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, approximately $43 million below the $933 million consensus estimate. The EP segment has been positioned as the primary growth engine for the company, driven by its FARAPULSE pulsed field ablation system and related cardiac rhythm management products.

The electrophysiology market represents one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential replacement for traditional thermal ablation procedures. Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has invested heavily in expanding manufacturing capacity and physician training programs. The company projected that global PFA penetration would reach 50% by the end of 2025 and grow to approximately 80% by 2028.

During the Q3 2025 earnings call on October 22, 2025, CEO Mike Mahoney stated the company was "guiding to organic growth of 11% to 13% for fourth quarter '25" and expressed that the company was "incredibly proud of our EP performance, with third quarter sales growing 63%." The company had emphasized EP growth rates of 94% in Q2 2025 and 63% in Q3 2025.

During the first Q&A exchange following the Q4 2025 earnings release, analysts noted the street was expecting approximately 25% EP growth for the quarter. Management's discussion indicated confidence in only approximately 15% growth going forward, representing a significant gap between market expectations and the company's internal outlook.

Following the earnings release, BSX shares fell 17.5% with the stock reaching a 52-week low of $75.50.

If you suffered a loss on your Boston Scientific Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283172

Source: Levi & Korsinsky, LLP

Remote-First-Company/SANTA CLARA, Calif.--(BUSINESS WIRE)--For America's most anticipated football game, Coinbase designed a shared, high-energy karaoke experience for its community to participate in together.

VANCOUVER, BC, /PRNewswire/ -- Abitibi Metals Corp. (CSE:AMQ) (OTCQB:AMQFF) has taken a major step forward in establishing itself as a serious emerging copper-gold developer in Québec's Abitibi Greenstone Belt.

The updated estimate shows a 124% increase in total mineral resources since Abitibi optioned the project in 2023, reflecting the results of successive drilling campaigns completed over the past two years. 

Abitibi Metals Delivers 12.83% CuEq at B26 as High-Grade Zone Continues to Grow The update expands the Indicated resource to 13.0 million tonnes (Mt) grading 2.1% copper equivalent (CuEq) and defines an additional 12.3 Mt Inferred resources grading 2.2% CuEq, bringing total defined resources to more than 25 Mt.

According to the company, the growth in tonnage has been achieved while maintaining consistent grades across the deposit, a key objective outlined when Abitibi acquired its interest in B26.

A Resource That Has Crossed an Important Threshold

The updated mineral resource estimate for the B26 deposit is supported by a substantially expanded technical database, incorporating 356 drill holes totaling 172,164 metres of drilling. This includes 102 drill holes completed by Abitibi Metals Corp. (CSE:AMQ) (OTCQB:AMQFF) in 2024 and 2025, as well as 191 holes previously drilled by SOQUEM, a subsidiary of Investissement Québec.

Within the Indicated category, resources increased 14% to 13.0 million tonnes, up from 11.3 million tonnes in the prior estimate. The Indicated resource grades 1.2% copper, 1.2% zinc, 0.44 g/t gold, and 30.8 g/t silver, equivalent to 2.1% copper equivalent and 2.8 g/t gold equivalent. 

On a contained metal basis, the Indicated resource includes approximately 340 million pounds of copper, 332 million pounds of zinc, 184 thousand ounces of gold, and 12.8 million ounces of silver, or 595 million pounds of copper equivalent and 1.2 million ounces of gold equivalent.

The estimate also includes 67,842 assays with an average sample length of 1.20 metres, forming the basis of the current geological model. The mineral resource was estimated using an underground mining scenario with an in-situ cut-off value of US$100 per tonne, based on long-term metal price assumptions and established processing recoveries.

Approximately 9% of the tonnage increase in the updated estimate is attributable to revised commodity price assumptions, with the balance driven by additional drilling and the lateral and vertical extension of existing mineralized zones. The effective date of the mineral resource estimate is January 1, 2026, and the estimate was prepared in accordance with NI 43-101 and CIM standards.

Growth Across All Metals, Not Just Tonnage

In addition to increased tonnage, the updated resource reflects material growth in contained metal across all reported commodities compared with the prior estimate.

Contained copper increased by 40%, gold by 22%, silver by 21%, and zinc by 9%. These increases reflect continued expansion of the polymetallic system across both Indicated and Inferred resource categories.

The resource estimate was completed using conservative underground cut-off assumptions and long-term pricing inputs, consistent with prior estimates.

Mineralization Remains Open With Drilling Momentum Building

Despite the increase in defined resources, mineralization at B26 remains open both laterally and at depth. The current estimate is based on drilling concentrated within established zones, leaving multiple areas available for further step-out and down-plunge drilling.

Abitibi Metals Corp. (CSE:AMQ) (OTCQB:AMQFF) has commenced a fully funded 40,000-metre Phase 4 drill program, which includes a winter drilling campaign of approximately 15,000 to 20,000 metres. Drilling is expected to continue through 2026.

A Cornerstone Asset in the Abitibi Greenstone Belt

B26 is located just seven kilometres from the former Selbaie mine, placing it within an established mining district with access to infrastructure, skilled labor, and a long history of successful development.

The deposit has now reached a level of scale and continuity that supports its advancement as a cornerstone copper-gold VMS asset within the Abitibi Greenstone Belt. As the resource continues to grow, B26 increasingly anchors Abitibi Metals' broader strategy of building a high-quality portfolio focused on Québec.

About Abitibi Metals Corp.

Abitibi Metals Corp. is dedicated to acquiring and exploring mineral properties within Quebec, with a particular emphasis on high-quality base and precious metal assets that offer significant potential for growth and expansion.

The company's flagship B26 Polymetallic project, which has been optioned from SOQUEM, hosts a substantial and growing resource base.

The B26 project is strategically located just 7 kilometres southeast of the formerly producing Selbaie mine. This proximity provides the project with access to key infrastructure required for potential mine development.

In addition to the B26 Deposit, Abitibi's portfolio includes the Beschefer Gold project, historical drilling has identified four notable, historical intercepts with a metal factor of over 100 g/t gold highlighted by 55.63 g/t gold over 5.57 metres (BE13-038) and 13.07 g/t gold over 8.75 metres (BE12-014) amongst four modelled zones.  These promising findings highlight the potential for further gold discoveries within the project area.

About SOQUEM:

SOQUEM, a mineral exploration company and subsidiary of Investissement Québec, is dedicated to promoting the exploration, discovery and development of mining properties in Quebec. SOQUEM also contributes to maintaining strong local economies. Proud partner and ambassador for the development of Quebec's mineral wealth, SOQUEM relies on innovation, research and strategic minerals to be well-positioned for the future. 

ON BEHALF OF THE BOARD

Jonathon Deluce, Chief Executive Officer 

For more information, please call +1 226-271-5170, email [email protected], or visit https://www.abitibimetals.com. 

The Company also maintains an active presence on various social media platforms to keep stakeholders and the general public informed and encourages shareholders and interested parties to follow and engage with the Company through the following channels to stay updated with the latest news, industry insights, and corporate announcements:

Twitter: https://twitter.com/AbitibiMetals

LinkedIn: https://www.linkedin.com/company/abitibi-metals-corp-amq-c/

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statement:

This news release contains certain statements, which may constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking information involves statements that are not based on historical information but rather relate to future operations, strategies, financial results or other developments on the B26 Project or otherwise. Forward-looking information is necessarily based upon estimates and assumptions, which are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the Company's control and many of which, regarding future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by or on the Company's behalf. Although Abitibi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. All factors should be considered carefully, and readers should not place undue reliance on Abitibi's forward-looking information. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects," "estimates," "anticipates," or variations of such words and phrases (including negative and grammatical variations) or statements that certain actions, events or results "may," "could," "might" or "occur.  Mineral exploration and development are highly speculative and are characterized by a number of significant inherent risks, which may result in the inability of the Company to successfully develop current or proposed projects for commercial, technical, political, regulatory or financial reasons, or if successfully developed, may not remain economically viable for their mine life owing to any of the foregoing reasons, among others. There is no assurance that the Company will be successful in achieving commercial mineral production and the likelihood of success must be considered in light of the stage of operations.

Disclaimer

1) The author of the Article, or members of the author's immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, Abitibi Metals Corp.. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Abitibi Metals Corp.'s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.'s engagement by Abitibi Metals Corp.'s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-amq.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use (https://pressreach.com/terms-of-use/) and full legal disclaimer as set forth here (https://pressreach.com/disclaimer/). This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation, (collectively, "forward-looking statements"), which reflect management's expectations regarding Abitibi Metals Corp.'s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Abitibi Metals Corp.'s industry; (b) market opportunity; (c) Abitibi Metals Corp.'s business plans and strategies; (d) services that Abitibi Metals Corp. intends to offer; (e) Abitibi Metals Corp.'s milestone projections and targets; (f) Abitibi Metals Corp.'s expectations regarding receipt of approval for regulatory applications; (g) Abitibi Metals Corp.'s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Abitibi Metals Corp.'s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Abitibi Metals Corp.'s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Abitibi Metals Corp.'s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Abitibi Metals Corp.'s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Abitibi Metals Corp.'s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Abitibi Metals Corp. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Abitibi Metals Corp.'s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Abitibi Metals Corp.'s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Abitibi Metals Corp.'s business operations (e) Abitibi Metals Corp. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, Abitibi Metals Corp. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Abitibi Metals Corp. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Abitibi Metals Corp. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Abitibi Metals Corp. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Abitibi Metals Corp. or such entities and are not necessarily indicative of future performance of Abitibi Metals Corp. or such entities.

8) The technical information contained in articles and videos produced for this campaign has been reviewed and approved by Martin Demers, P.Geo., OGQ No. 770 at Abitibi Metals Corp. as the Qualified Person for the Company as defined in National Instrument 43-101.

9) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

Contact:
Chief Executive Officer
Jonathon Deluce
Abitibi Metals Corp.
[email protected]

Photo: https://mma.prnewswire.com/media/2889040/Abitibi_Metals_Corp_High_Grade_Zone.jpg
Logo: https://mma.prnewswire.com/media/2889039/Abitibi_Metals_Corp_Logo.jpg

SOURCE Abitibi Metals Corp.

Agreement will leverage Evinova’s innovative AI-native platform to improve trial design, accelerate timelines, and enhance cost efficiency

BAAR, Switzerland--(BUSINESS WIRE)--Evinova today announced that Bristol Myers Squibb has signed an agreement to optimize clinical trials with Evinova’s AI-native clinical development platform. Under the terms of the agreement, Bristol Myers Squibb will deploy the Cost Optimizer module of Evinova’s Study Designer across the company’s global portfolio, harnessing advanced artificial intelligence to improve insight-driven decision making, identify productivity opportunities, and unlock more efficient trial designs that accelerate innovation and improve experience for sites and patients.

This partnership will harness advanced artificial intelligence to improve insight-driven decision making, identify productivity opportunities, and unlock more efficient trial designs that accelerate innovation and improve experience for sites and patients.

Share “Drug development is changing rapidly, and life science companies need partners who bring both AI leadership and clinical development expertise to successfully drive transformation,” said Cristina Duran, President of Evinova. “Evinova, founded by pharma for pharma, combines AI innovation with deep industry insight to reimagine clinical development. We’re thrilled to collaborate with Bristol Myers Squibb to drive efficiencies in drug development and accelerate breakthroughs for patients.”

“Transforming clinical development is not just an opportunity; it is an urgent necessity,” said Cristian Massacesi, MD, EVP, Chief Medical Officer & Head of Development at Bristol Myers Squibb. “For years, developing medicines has taken too long, cost too much money, and mostly resulted in failure. Digital tools and AI can help us overcome these limitations and lay the foundation for better health outcomes for countless individuals in the years to come. The decisions we make now will shape the future of medicine, accelerate progress and ensure that the benefits of scientific advancement reach those who need them most.”

Enhancing Value with Evinova’s AI-Native Platform Solutions

Evinova's industry-leading AI-native platform for clinical development harnesses agentic AI to enhance study design, streamlines processes through collaboration and enables seamless digital data flow in USDM standards. The platform also incorporates robust controls and safeguards to ensure the responsible integration of AI into clinical development. The end-to-end platform is globally scaled and brings together functionality that has delivered hundreds of millions of dollars in multi-year savings for customers.

Complementing the trial optimization solutions, Evinova’s Unified Trial Solution integrates critical study elements into an improved, connected trial experience for sponsors, sites and patients. The Unified Trial Solution app seamlessly integrates eCOA with telehealth and connected devices for remote patient monitoring (RPM) for toxicity management, removing friction points and enabling robust data collection for novel endpoints and innovative trial designs. Evinova’s human-centered approach to product development incorporates input from patients and trial site teams, evidenced by industry-leading eCOA compliance metrics and user engagement scores.

Solutions on Evinova’s AI platform are proven to accelerate timelines, reduce costs, improve data quality, enhance patient experiences, reduce the duration of adverse events and ultimately achieve better outcomes.

Partner with Us to Advance Clinical Development

Evinova invites forward-thinking organizations to join us in redefining a future where clinical development is faster, more efficient, and truly patient-centric. Pharma, biotech and CROs interested in working with us can reach out here.

About Evinova

Evinova empowers life science leaders to accelerate better health outcomes. Purpose-built by healthcare for healthcare, Evinova delivers intelligently designed digital and AI-native solutions that optimize the entire clinical development lifecycle from end to end. With proven outcomes published in Nature Medicine, Evinova’s solutions and strategies have demonstrated up to 60% improvement in patient experience, 6-month acceleration in trial delivery, and 32% reduction in costs. Evinova is a separate health tech company within the AstraZeneca group. Learn more about Evinova at www.evinova.com or on social media @Evinova.

, /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed GeminiOne Transcatheter Edge-to-Edge Repair (TEER) System for the treatment of mitral regurgitation, with HighLife SAS being the Company's European partner.

The CE Mark submission represents a significant milestone in Peijia Medical's globalization strategy and underscores the Company's continued commitment to expanding its presence in major international markets.

GeminiOne is a novel TEER device internally developed by the Company. The system features a unique sliding groove mechanism that enables a longer coaptation length while maintaining a smaller implant size and delivery system. It also incorporates an independent leaflet grasping design intended to reduce procedural complexity, an auto-locking mechanism that helps prevent repeated locking and unlocking during the procedure, and a multi-angular detachment capability that allows the device to accommodate a wider range of anatomical variations. The design of the System has been patented globally and has obtained clearance through multiple freedom-to-operate (FTO) analyses.

In addition to the EU submission, the registration application for GeminiOne has been accepted by the National Medical Products Administration (NMPA) of the People's Republic of China and is currently under review. The system has also received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (U.S. FDA) to conduct an Early Feasibility Study (EFS) in the United States.

Peijia Medical will continue to actively advance regulatory registrations in China and Europe, aiming to bring safe and effective treatment options to patients with mitral regurgitation at the earliest practicable opportunity.

Forward-Looking Statements

This press release contains forward-looking statements related to product availability, clinical development, and commercialization plans. Actual results may differ due to regulatory, clinical, or market factors.

Regulatory Notice

The GeminiOne TEER System is currently under clinical and regulatory evaluation and has not been approved for commercial sale in any country or region.

About the Company

Peijia Medical (9996.HK) was established in 2012 and is headquartered in Suzhou, China. Peijia Medical focuses on the high-growth interventional procedural medical device market in China and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases. The Company now has four TAVR systems and nearly twenty neurointerventional devices registered in China and various innovative product candidates at different stages of development. For more information about Peijia visit peijiamedical.com/about.

SOURCE Peijia Medical

WISeKey’s WISe.Art and GMA Once Again Revolutionize the Future of Art and Technology in an Extraordinary Event in Venice

Geneva, Switzerland, February 9, 2026 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its subsidiary, WISe.Art which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and Global Market of Artification (GMA) is an innovative company, focused on offering NFT services, will be organizing Art&DeepTech Convergence, an international event and exhibition that will mark a new, fundamental milestone in the convergence of art, advanced technologies, and space in Venice, Italy in September 2026. Venice, cradle of the Renaissance and historic crossroads of cultures, will become the global laboratory of a new creative era, where technological innovation is placed at the service of artistic expression and human values.

A Technological Infrastructure Serving Artistic Creation
Art&DeepTech Convergence is built upon a next-generation technological infrastructure integrating generative artificial intelligence, cognitive robotics, advanced blockchain, certified tokenization, post-quantum cybersecurity, and satellite connectivity. The event will demonstrate how these technologies do not replace the artist, but rather amplify creative capacity, protect artworks, and enable global dissemination.

Both digital and physical artworks will be registered and protected through certified digital identity systems, ensuring authenticity, traceability, copyright protection, and continuity over time, even within digital and decentralized environments.

Art in Space: The WISeSat Constellation as a New Cultural Frontier
A defining feature of the event will be the Art in Space program, which leverages WISeKey’s WISeSat satellite constellation as an orbital cultural infrastructure. WISeSat, another subsidiary of WISeKey, focuses on space technology for secure satellite communication, specifically for IoT applications. Through secure end-to-end connections and certified transmission systems, selected artistic content will be associated with space missions, creating a symbolic and technological archive of 21st-century art.

Space thus becomes not only a technological domain, but a new narrative and cultural space, where art takes on a universal and intergenerational dimension.

WISeRobots and Human-Centric Artificial Intelligence
Within the exhibition spaces, WISeRobots will operate as intelligent cultural mediators, powered by conversational AI models trained on artistic, historical, and critical content. These robots will be able to engage in dialogue with visitors, adapt language to context, facilitate interactions during round tables, and collect real-time feedback, transforming the visit into a personalized and dynamic experience.

The AI employed will follow a human-centric and ethical approach, designed to enhance cultural diversity, creativity, and critical thinking.

Digital Immersion and AI-Generated Environments
The exhibition journey will include advanced digital immersion environments generated by AI and accessed through multisensory installations. Images, sounds, data, and narratives will be created and transformed in real time, giving rise to evolving artistic universes in which the visitor is not a passive observer, but an integral part of the artwork.

These environments represent a new exhibition paradigm: art as a living system, capable of reacting, learning, and evolving over time.

Renaissance Coin and Artech Fund: Technology and Cultural Finance
During the event, the Renaissance Coin, based on secure and sustainable blockchain technologies, and the Artech Fund, a fund dedicated to supporting high-tech artistic projects, will be launched. Together, these initiatives introduce new models of transparent cultural finance, enabling artists to access global resources and allowing investors to actively participate in the development of the art of the future.

A Global Platform of Artists and Innovators
Thousands of artists already active on the WISe.ART platform will take part in the event, presenting works that integrate AI, data, robotics, and immersive media. Venice will thus become the physical hub of a global creative network, where technology enables collaboration, inclusion, and the protection of artistic value on a worldwide scale.

Venice 2026: A Technological and Human Renaissance
With Art&DeepTech Convergence, WISe.ART and GMA affirm a clear vision: the future of art passes through technology, but remains profoundly human. Venice 2026 will stand as the symbol of a new Renaissance, where space, artificial intelligence, digital security, and creativity converge to build a more open, secure, and universal cultural future.

About WISe.ART
WISe.ART is a convergence platform at the intersection of art, technology, and trust, designed to redefine how digital art is created, protected, distributed, and preserved over time. Built on WISeKey’s deep expertise in cybersecurity, digital identity, and blockchain technologies, WISe.ART offers a secure and sovereign NFT ecosystem connecting artists, collectors, cultural institutions, and technology innovators worldwide.

At its core, WISe.ART ensures the provenance, authenticity, and longevity of digital artworks by embedding trusted digital identities and cryptographic certificates directly into each creation. These protections are further strengthened through post-quantum cryptography, leveraging SEALSQ’s quantum-resistant technologies to future-proof artworks against the next generation of cyber threats and quantum computing attacks.

WISe.ART also introduces a unique dimension of satellite-enabled art connectivity through the WISeSat constellation, enabling art projects that are globally accessible, resilient, and independent of traditional terrestrial networks. This allows artists and institutions to deploy, synchronize, and authenticate digital artworks across borders, remote locations, exhibitions, and even space-enabled installations, ensuring continuous availability and sovereign data control.

Beyond a marketplace, WISe.ART acts as a living laboratory for the convergence of art and advanced technologies, combining blockchain, AI, robotics, satellite communications, and quantum-safe security. It empowers artists to explore new creative frontiers while providing collectors and institutions with absolute confidence that the artworks they acquire are secure, verifiable, tamper-proof, and enduring.

By merging human creativity with trusted, post-quantum and space-based digital infrastructure, WISe.ART lays the foundation for a new cultural era, where art is not only created for the future, but protected for it.

About GMA:
Global Market of Artification (GMA) is an innovative company, focused on offering NFT services. GMA offers a unique tokenisation experience, enabling a new form of investment in world-renowned artworks. The platform enables the creation of an NFT that represents the digital rights of the artwork granted by the artwork’s owner through a legal contract. All the transactions are managed by the underlying Ethereum Blockchain.

About WISeKey

WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

Press and Investor Contacts

WISeKey International Holding Ltd
Company Contact: Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected] WISeKey Investor Relations (US) 
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
[email protected]

I initiate BridgeBio with a Neutral rating and a $74 target price, reflecting balanced opportunity and risk. ATTR-CM launch of Attruby reduces binary risk, but commercial sustainability and pricing durability remain uncertain amid competitive pressures. Pipeline assets like encaleret and BBP-418 offer optionality but lack near-term cash flow and face regulatory hurdles.

Unicredit logo is seen in this illustration taken December 3, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

MILAN, Feb 9 (Reuters) - Italy's second-largest bank UniCredit (CRDI.MI), opens new tab said it aimed to lift its profit to 11 billion euros ($13 billion) this year, after topping analysts' forecasts for 2025 with earnings boosted by stakes in rivals bought under CEO Andrea Orcel's expansion strategy.

UniCredit, which had previously guided for a net profit of 10 billion euros in 2027, said on Monday it had an ambition to get to 13 billion euros in 2028 with "exceptional" average growth of 7% a year in 2026 to 2028.

The Week in Breakingviews newsletter offers insights and ideas from Reuters' global financial commentary team. Sign up here.

UniCredit has spent billions of euros from its large excess cash reserves to become the main shareholder in Germany's Commerzbank (CBKG.DE), opens new tab and Greece's Alpha Bank (ACBr.AT), opens new tab, though it has stopped short of full takeovers.

Under the leadership of Orcel, a veteran dealmaker, UniCredit has also invested, sometimes temporarily, in other financial institutions in what Mediobanca Securities analysts have dubbed a "game of stakes".

The bank, which also has large operations in Germany, Austria and eastern Europe, posted a net profit of 2.17 billion euros for the fourth quarter, benefiting from 336 million euros of tax credits from past losses to surpass a bank-gathered average analyst forecast of 1.96 billion euros.

($1 = 0.8450 euros)

Reporting by Valentina Za; Editing by Sonali Paul and Jamie Freed

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Feb 9 (Reuters) - Chemicals company DSM-Firmenich (DSFIR.AS), opens new tab has agreed to sell its Animal Nutrition & Health business to CVC Capital (CVC.AS), opens new tab for an enterprise value of around 2.2 billion euros ($2.6 billion), it said on Monday.

DSM-Firmenich said it would receive about 1.2 billion euros as part of the deal, with a potential further earn out of 500 million euros. It will retain a 20% stake in the divested business.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The deal follows the sale of its feed enzymes activities for 1.5 billion euros in 2025 and "marks the final strategic step for dsm-firmenich to become a fully focused consumer company active in nutrition, health, and beauty", the company said in a press release.

The divestment, which is expected to be closed at the end of 2026, will result in a non-cash impairment of around 1.9 billion euros before taxes in 2025, with cash tax, transaction and separation costs of 200 million euros expected in 2026, DSM-Firmenich said.

The company also said it planned to launch a 500-million-euro share buyback programme in the first quarter of 2026.

($1 = 0.8445 euros)

Reporting by Jakob Van Calster in Gdansk, editing by Milla Nissi-Prussak

Our Standards: The Thomson Reuters Trust Principles., opens new tab